USPTO serial 79294792
OMASS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 10, 2021
- Examiner
- FITZSIMONS, MICHAEL R
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with OMASS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; biopharmaceutical preparations for treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; chemical, biochemical and biological preparations for medical and veterinary purposes for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; reagents for medical use, namely reagents for in-vitro laboratory use cells for medical or clinical use, namely cells, cell lines, and cell cultures for use in the production of proteins for therapeutic use; reagents for medical use; biological reagents for medical use; therapeutic antibodies; vaccines | ACTIVE | — |
| 042 | Scientific and technological services, namely scientific research and development; laboratory research services in the field of chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; medical and pharmacological research services; scientific research, namely, analysis and measurement of substances; analysis and measurement of molecules and characteristics; bioanalysis services; scientific imaging services; biochemical analysis; scientific research and development services; medical research; research and development in the fields of immunology, genetic conditions, oncology, immuno-oncology, ophthalmology, haematology, neurology, respiratory diseases, metabolic conditions, infectious diseases and cardiovascular diseases; pharmaceutical research and development services; biological research and analysis; biomedical research services; biotechnology research; biotechnology research, namely, biotechnology testing; chemical research and analysis; research and development of new products for others in the biotechnical, biomedical and pharmaceutical fields; research and development in the pharmaceutical field; research and development of vaccines and medicines; research and development services in the field of antibodies; research and development services in the field of antibody technology; research and development services in the field of immunology; medical laboratory services; research of pharmaceuticals; research relating to molecular sciences; research relating to pharmaceuticals; biopharmaceutical research, development and testing services; drug discovery services; drug development services; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; research and development of molecules for therapeutic purposes; consultancy, advisory and/or information services in relation to all the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by OMASS Therapeutics Limited
- Other trademarks owned by OMASS Therapeutics Limited
- Other trademarks owned by OMASS Therapeutics Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named OMASS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 10, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 7, 2023 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 14, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 24, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 24, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 10, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 10, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 30, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 25, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 25, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 10, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 5, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 5, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 20, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 15, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 14, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 14, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 29, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 22, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 2, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 2, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 10, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 10, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 9, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 6, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 6, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 1, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |